Home

Greenwich LifeSciences, Inc. - Common stock (GLSI)

12.00
+0.22 (1.87%)

Greenwich Lifesciences Inc is a biotechnology firm focused on advancing innovative therapies for cancer treatment, particularly in the realm of immunotherapy

The company is dedicated to developing its novel drug candidates to harness the body's immune system in targeting and destroying cancer cells. Through rigorous research and clinical trials, Greenwich Lifesciences aims to provide effective treatment options for patients, with a specific emphasis on improving outcomes and quality of life for those affected by various types of cancer. The firm's commitment to scientific excellence and patient-centric approaches positions it at the forefront of cancer therapeutics.

SummaryNewsPress ReleasesChartHistoricalFAQ
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQGLSI) concerning the Company and its directors’ and officers’ possible violations of state laws.
By Glancy Prongay & Murray LLP · Via Business Wire · January 17, 2025
Greenwich LifeSciences Inc. (NASDAQ: GLSI) Near the Top of Equities by Percentage Gain on 2/14
Greenwich LifeSciences, Inc. (NASDAQGLSI) is one of today’s top gainers. The company’s shares have moved 33.96% on the day to $11.13.
Via Investor Brand Network · February 14, 2024
Greenwich LifeSciences Provides Year End Update
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 29, 2022
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2023 which is approximately 39 months from date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 1, 2022
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:
By Greenwich LifeSciences, Inc. · Via Business Wire · August 11, 2022
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:
By Greenwich LifeSciences, Inc. · Via Business Wire · August 3, 2022
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:
By Greenwich LifeSciences, Inc. · Via Business Wire · July 28, 2022
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed.
By Greenwich LifeSciences, Inc. · Via Business Wire · July 12, 2022
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program.
By Greenwich LifeSciences, Inc. · Via Business Wire · July 11, 2022
Greenwich LifeSciences to Resume Stock Repurchase Program
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program.
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming investor, partnering, and scientific conferences:
By Greenwich LifeSciences, Inc. · Via Business Wire · April 20, 2022
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:
By Greenwich LifeSciences, Inc. · Via Business Wire · April 19, 2022
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will present in-person at 2:30 pm ET on February 14, 2022 at the 2022 BIO CEO & Investor Conference and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
By Greenwich LifeSciences, Inc. · Via Business Wire · February 3, 2022
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides an update on the Phase III clinical trial, FLAMINGO-01.
By Greenwich LifeSciences, Inc. · Via Business Wire · February 1, 2022
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has authorized the Company’s management to implement a stock repurchase program for up to $10 million of the Company's common stock at any time.
By Greenwich LifeSciences, Inc. · Via Business Wire · January 24, 2022
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that CEO Snehal Patel participated in a TD Ameritrade interview to discuss the Phase IIb poster presented at the 2021 San Antonio Breast Cancer Symposium on December 9, 2021.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 15, 2021
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a poster for the GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium 2021 (SABCS). The CEO of Greenwich LifeSciences, Snehal Patel, recorded an audio track providing an overview. The abstract can be viewed at the bottom of this press release. The full poster with figures, tables, and audio can be accessed or downloaded from the Company’s website here.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 9, 2021
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that the Company will participate in the following interviews and conferences.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 8, 2021
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the expansion of Dr. F. Joseph Daugherty’s role to include the critical responsibility of Medical Monitor of the Phase III clinical trial and a long-term agreement to serve as Chief Medical Officer.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 7, 2021
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides manufacturing and clinical updates on Phase III clinical trial FLAMINGO-01.
By Greenwich LifeSciences, Inc. · Via Business Wire · December 6, 2021
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that an exclusive interview with CEO Snehal Patel will air on the upcoming The RedChip Money Report® on Bloomberg TV, this Saturday November 20th at 7 pm ET. Bloomberg TV airs in an estimated 73 million homes across the United States.
By Greenwich LifeSciences, Inc. · Via Business Wire · November 18, 2021
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced CEO Snehal Patel will participate in the virtual portion of Jefferies’ Annual London Healthcare Conference held from November 16-19, 2021.
By Greenwich LifeSciences, Inc. · Via Business Wire · November 17, 2021
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that two abstracts and posters have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS).
By Greenwich LifeSciences, Inc. · Via Business Wire · November 11, 2021
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides an update on the upcoming Phase III clinical trial FLAMINGO-01.
By Greenwich LifeSciences, Inc. · Via Business Wire · November 10, 2021